The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 13, 2024

Filed:

Mar. 01, 2021
Applicant:

North Carolina State University, Raleigh, NC (US);

Inventors:

Zhen Gu, Raleigh, NC (US);

Chao Wang, Raleigh, NC (US);

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/28 (2006.01); A61K 47/54 (2017.01); A61K 47/69 (2017.01); C07H 13/08 (2006.01); A61K 47/60 (2017.01); A61K 47/64 (2017.01); A61P 3/10 (2006.01); A61K 9/00 (2006.01); A61K 35/18 (2015.01);
U.S. Cl.
CPC ...
A61K 47/549 (2017.08); A61K 9/0021 (2013.01); A61K 35/18 (2013.01); A61K 38/28 (2013.01); A61K 47/60 (2017.08); A61K 47/64 (2017.08); A61K 47/6937 (2017.08); A61P 3/10 (2018.01); C07H 13/08 (2013.01);
Abstract

Disclosed herein is a glucose-responsive insulin delivery system based on the interaction between the glucose-modified insulin and glucose transporters (GLUTs) on erythrocytes (or red blood cells, RBCs). After being conjugated with glucose, insulin can efficiently bind to RBC membranes. The binding is reversible in the setting of hyperglycemia, resulting in fast release of insulin and subsequent drop of blood glucose (BG) level in vivo. In some embodiments, the delivery vehicle can include: 1) intravenously injectable polymeric nanoparticles (˜100 nm in diameter) coated with RBC membrane and loaded with glucose-modified insulin and/or 2) painless microneedle (MN) patches loaded with the complex of GLUT and glucose-modified insulin.


Find Patent Forward Citations

Loading…